Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Stakeholder Opinions: Multiple Myeloma - Exploring new targets for multiple drug therapy' returned 2 results - Page 1 of 1   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes - Optimization of clinical practice creates opportunities for emerging therapies   Datamonitor, April 2010, Pages: 243 are targeted therapies. Non-Hodgkin's lymphomas are targeted by drug developers more often than Hodgkin's lymphoma, multiple myeloma or myelodysplastic syndromes Targeted therapies account for over half of non Stakeholder Opinions: Bone Metastases - Impending Patent Expiries May Help Make or Break Newer Agents   Datamonitor, March 2008, Pages: 100 Patients may be on bisphosphonates for too long 55 New therapies required to improve current poor patient survival 56 Drugs needed to specifically target osteoblastic metastases 56 Summary of unmet needs 57 Results:  First -   Prev -   1 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network